Clinical trial
A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
NCT02232633 is registered in ClinicalTrials.gov with Sumitomo Pharma America, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2015
- Completion date
- December 14, 2017
- Enrollment
- 45 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
cholangiocarcinoma, hepatocellular carcinoma